Abstract
Cdc25 phosphatases, as activators of the Cdk/cyclins, play critical roles in the regulation of the eukaryotic cell cycle. Because of their overexpression and correlation with poor prognosis in many diverse cancers, Cdc25 phosphatases are attractive targets for anticancer drug development. Over the past few years, much knowledge of the basic enzymology of the Cdc25 phosphatases that may aid in the development of specific inhibitors has been gained. We review herein the structure, specificity, and mechanism of the Cdc25 phosphatases with a special focus on the activity of Cdc25 phosphatases with native protein substrates.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Binding Sites
-
Cell Cycle* / drug effects
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Gene Expression Regulation, Enzymologic* / drug effects
-
Gene Expression Regulation, Neoplastic* / drug effects
-
Humans
-
Neoplasm Proteins / biosynthesis*
-
Neoplasms / drug therapy
-
Neoplasms / enzymology*
-
Neoplasms / pathology
-
Protein Structure, Secondary
-
Protein Structure, Tertiary
-
Substrate Specificity / drug effects
-
cdc25 Phosphatases / antagonists & inhibitors
-
cdc25 Phosphatases / biosynthesis*
-
cdc25 Phosphatases / chemistry
Substances
-
Enzyme Inhibitors
-
Neoplasm Proteins
-
cdc25 Phosphatases